Klaus Seppi and Marina Peball (Innsbruck Medical University, Innsbruck, Austria) both kindly joined touchNEUROLOGY to share the promising results from their presentation entitled: Effects of Nabilone on Non-motor Symptoms of Parkinson’s Disease – A Randomised Placebo-controlled Study (The NMS-Nab Study). ClinicalTrials.gov identifier: NCT03769896.
Questions
1. Could you give us a brief overview of non-motor symptoms in Parkinson’s disease (PD) and the unmet needs in their management? (0:06)
2. What is the rationale for the use of nabilone for the treatment of non-motor symptoms in PD? (0:54)
3. Could you tell us about the NMS-Nab study and its findings? (2:30)
4. Which patients are likely to respond best to nabilone and in whom should it be used with caution? (4:10)
5. What are the implications for these findings or the future investigation of cannabinoids, and what future studies are planned? (4:33)
Disclosures: Klaus Seppi reports receiving personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Grünenthal and Abbvie, honoraria from the International Parkinson and Movement Disorders Society, research grants from FWF Austrian Science Fund, Michael J. Fox Foundation, and International Parkinson and Movement Disorder Society. Marina Peball reports receiving travel compensation for presentation of the study data after study end from AOP Orphan Pharmaceuticals AG, which manufactures the drug that is tested in this study.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
